Last reviewed · How we verify

RIMANTADINE

FDA-approved approved Small molecule ✓ Verified May 2026 Quality 10/100

RIMANTADINE is a drug. It is currently FDA-approved (first approved 1993).

Rimantadine is used to study and treat conditions such as influenza, pulmonary disease, chronic obstructive pulmonary disease, bronchospasm, and asthma. It is often compared to other antiviral medications like oseltamivir (Tamiflu) in clinical trials for its effectiveness in preventing and treating influenza.

At a glance

Generic nameRIMANTADINE
ModalitySmall molecule
PhaseFDA-approved
First approval1993

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about RIMANTADINE

What is RIMANTADINE?

RIMANTADINE is a Small molecule drug.

When was RIMANTADINE approved?

RIMANTADINE was first approved on 1993.

What development phase is RIMANTADINE in?

RIMANTADINE is FDA-approved (marketed).

What are the side effects of RIMANTADINE?

Common side effects of RIMANTADINE include Insomnia, Dizziness, Headache, Nervousness, Fatigue, Nausea.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing